Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urgent MG study of early C5 inhibitor intervention in generalized myasthenia gravis
jRCTs071260022Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of ravulizumab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Primary endpoint: Change from baseline in MG-ADL score at 26 weeks. Started Sep 2026; status: recruiting.
02
Drugs
ravulizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCTs071260022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071260022.